WuXi Beats Financial Estimates in Q1
May 10, 2011 at 13:10 PM EDT
WuXi PharmaTech, one of China’s most visible CRO/CMOs, reported first quarter revenues that were slightly better than expected, up 16% at $93.6 million. The company’s lab service revenues increased 12%, but the star performer was contract manufacturing, which climbed 35% to $19.1 million. GAAP net income was up 17% at $18.2 million, or 24 cents per share. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues:
